Chaperone-enzyme replacement therapy product - Amicus/JCR Pharmaceuticals

Drug Profile

Chaperone-enzyme replacement therapy product - Amicus/JCR Pharmaceuticals

Alternative Names: Alpha-galactosidase A/migalastat; Alpha-galactosidase/migalastat; AT-B100; Chaperone-ERT product - Amicus/JCR; JR-051/migalastat; Migalastat/alpha galactosidase; Migalastat/alpha galactosidase A; Migalastat/JR-051

Latest Information Update: 14 Apr 2016

Price : $50

At a glance

  • Originator Amicus Therapeutics
  • Developer Amicus Therapeutics; JCR Pharmaceuticals
  • Class Enzymes; Pharmacological chaperones; Piperidines; Recombinant proteins; Small molecules
  • Mechanism of Action Alpha-galactosidase stimulants; Protein folding stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Fabry's disease

Most Recent Events

  • 17 Jul 2012 Preclinical trials in Fabry's disease in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top